机构：[1]Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China,Department of Chemistry, Stanford University, Stanford, California 94305, United States[2]State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China[3]Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou 510515, China[4]Guangdong Provincial Key Laboratory of Biomedical Optical Imaging Technology & Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China[5]Jiangsu Co-innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, Nanjing Forestry University, Nanjing 210037, China[6]Department of Chemistry, Stanford University, Stanford, California 94305, United States[7]Department of Chemical Engineering, Imperial College London, London SW7 2AZ, United Kingdom[8]Jiangsu Co-innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, Nanjing Forestry University, Nanjing 210037, China[9]West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States[10]Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China, Department of Urology, Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China深圳市妇幼保健院深圳市康宁医院深圳市人民医院深圳市中医院深圳医学信息中心[11]West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China, School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, United States
Development of second near-infrared (NIR-II) nanoparticles (NPs) with high biocompatibility, low toxicity, and high singlet oxygen quantum yield (ΦΔ) to prevent tumor recurrence is highly desirable in molecular imaging and photodynamic/immune combination therapy. Here, theranostic photosensitizer BODIPY (BDP)-I-N-anti-PD-L1 NPs were developed by encapsulating the photosensitizer BDP-I-N with amphipathic poly(styrene-co-chloromethylstyrene)-graft-poly(ethylene glycol) nanocarriers through self-assembly functionalization with programmed cell death-ligand 1 (PD-L1) monoclonal antibody. These NPs exhibit highly intensive luminescence in the NIR-II window (1000-1700 nm) to real-time imaging of immune checkpoint PD-L1, high singlet oxygen quantum yield (ΦΔ = 73%), and an eliminating effect of primary cancers. The NPs also allow for profiling PD-L1 expression as well as accumulating in MC38 tumor and enabling molecular imaging in vivo. Upon an 808 nm laser excitation, the targeted NPs produce an emission wavelength above 1200 nm to image a tumor to a normal tissue signal ratio (T/NT) at an approximate value of 14.1. Moreover, the MC38 tumors in mice are eliminated by combining photodynamic therapy and immunotherapy within 30 days, with no tumor recurrence within a period of 40 days. In addition, the tumors do not grow in the rechallenged mice within 7 days of inoculation. Such a strategy shows a durable immune memory effect against tumor rechallenging without toxic side effects to major organs.
基金：
J.T. received funding for equipment from National Natural
Science Foundation of China (No. 21775166) and Natural
Science Foundation of Jiangsu Province (No. BK20180026).
Q.S. received funding from National Natural Science
Foundation of China (No.22077135). H.X. received funding
from Natural Science Foundation of Jiangsu Province
(BK20151513).
第一作者机构：[1]Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China,Department of Chemistry, Stanford University, Stanford, California 94305, United States
共同第一作者：
通讯作者：
通讯机构：[8]Jiangsu Co-innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, Nanjing Forestry University, Nanjing 210037, China[9]West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States[10]Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China, Department of Urology, Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China[11]West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China, School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, United States[*1]Jiangsu Co-innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, Nanjing Forestry University, Nanjing 210037, China[*2]West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States[*3]Artemisinin Research Center and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China, Department of Urology, Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China[*4]West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China, School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, United States
推荐引用方式(GB/T 7714)：
Qiang Liu,Jiangwei Tian,Ye Tian,et al.Near-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy.[J].ACS NANO.2021,15(1):515-525.doi:10.1021/acsnano.0c05317.
APA：
Qiang Liu,Jiangwei Tian,Ye Tian,Qinchao Sun,Dan Sun...&Nan Jiang.(2021).Near-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy..ACS NANO,15,(1)
MLA：
Qiang Liu,et al."Near-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy.".ACS NANO 15..1(2021):515-525
材料科学